Among these inhibitors, midostaurin was approved for newly diagnosed FLT3-ITD AML in combination with chemotherapy and gilteritinib was approved for resistant and relapsed FLT3-ITD AML [8, 9]. Here, FLT3 is linked to acute myeloid leukemia.